Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $3.7 million.

  • BioLineRx's Cash from Investing Activities fell 6390.17% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 23539.94%. This contributed to the annual value of $29.4 million for FY2024, which is 193421.05% up from last year.
  • Latest data reveals that BioLineRx reported Cash from Investing Activities of $3.7 million as of Q3 2025, which was down 6390.17% from -$3.7 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Cash from Investing Activities peaked at $16.7 million during Q1 2024, and registered a low of -$20.4 million during Q4 2023.
  • In the last 3 years, BioLineRx's Cash from Investing Activities had a median value of $4.1 million in 2023 and averaged $2.1 million.
  • Over the last 5 years, BioLineRx's Cash from Investing Activities had its largest YoY gain of 15470.46% in 2024, and its largest YoY loss of 17788.29% in 2024.
  • Quarter analysis of 3 years shows BioLineRx's Cash from Investing Activities stood at -$20.4 million in 2023, then soared by 154.7% to $11.2 million in 2024, then crashed by 67.08% to $3.7 million in 2025.
  • Its Cash from Investing Activities stands at $3.7 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$8.2 million for Q1 2025.